+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission



Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission



Haematologica 89(8): Ecr25




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 050334145

Download citation: RISBibTeXText

PMID: 15339694


Related references

Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-alpha positive idiopatic hypereosinophilic syndrome. Blood 102(11): 335b, 2003

Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome. Haematologica 89(2): 236-237, 2004

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 109(11): 4635-4640, 2007

FIP1L1-PDGFR alpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib. Chinese Medical Journal (English Edition) 121(10): 867-873, 2008

Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood 110(10): 3552-3556, 2007

The efficacy of imatinib mesylate in patients with FIP1L1-PDGFR alpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica The Hematology Journal 92(9): 1173-1179, 2007

Complete reversal of left ventricular mass in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia after therapy with imatinib. International Journal of Cardiology 151(3): E90, 2011

Successful imatinib treatment of cardiac involvement of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia followed by severe hepatotoxicity. International Journal of Hematology 86(3): 233-237, 2007

Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment. Haematologica 91(2): 162-168, 2006

FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia. Verhandelingen - Koninklijke Academie Voor Geneeskunde van Belgie 67(3): 169-176, 2005

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109(1): 58-60, 2007

Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia. Cancer ChemoTherapy and Pharmacology 67(4): 967-969, 2011

Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood 104(7): 1979-1988, 2004

Development of Löffler's endocarditis in FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome despite continuous imatinib mesylate therapy and continuous complete remission. American Journal of Hematology 85(4): 296-299, 2010

The efficacy of imatinib mesylate in patients with FIP1L1-PDGFR -positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 92(9): 1173-1179, 2007